Header cover image

Hong Kong (HSI) Biotech Industry Analysis

UpdatedAug 15, 2022
DataAggregated Company Financials
Companies37
  • 7D0.1%
  • 3M1.1%
  • 1Y-52.7%
  • YTD-35.7%

The Biotech is pretty flat in the last 7 days, but CARsgen Therapeutics Holdings has stood out, gaining 13%. As for the longer term, the industry has declined 53% in the last year. Looking forward, earnings are forecast to grow by 64% annually.

Industry Valuation and Performance

Has the Hong Kong Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 15 Aug 2022HK$337.1bHK$33.0b-HK$46,223,115,555.0012.2x-7.3x10.2x
Wed, 13 Jul 2022HK$354.5bHK$33.0b-HK$46,526,710,378.0014x-7.6x10.7x
Fri, 10 Jun 2022HK$356.6bHK$33.1b-HK$46,747,678,849.0013.8x-7.6x10.8x
Sun, 08 May 2022HK$314.0bHK$34.2b-HK$45,397,203,424.0012.8x-6.9x9.2x
Tue, 05 Apr 2022HK$365.1bHK$36.4b-HK$46,240,935,723.0015x-7.9x10x
Thu, 03 Mar 2022HK$335.5bHK$34.0b-HK$31,280,929,324.0014.3x-10.7x9.9x
Sat, 29 Jan 2022HK$293.1bHK$31.1b-HK$31,813,620,151.0011.3x-9.2x9.4x
Mon, 27 Dec 2021HK$403.2bHK$31.1b-HK$31,835,164,292.0013.2x-12.7x13x
Wed, 24 Nov 2021HK$508.2bHK$31.0b-HK$31,710,966,654.0013.1x-16x16.4x
Fri, 22 Oct 2021HK$498.3bHK$30.7b-HK$31,739,593,217.0015.2x-15.7x16.2x
Sun, 19 Sep 2021HK$523.9bHK$30.4b-HK$31,435,338,694.0016.9x-16.7x17.2x
Tue, 17 Aug 2021HK$529.4bHK$30.2b-HK$32,058,827,347.3514.9x-16.5x17.5x
Tue, 01 Jun 2021HK$629.6bHK$27.8b-HK$26,637,487,691.0921.6x-23.6x22.7x
Fri, 05 Mar 2021HK$546.6bHK$24.0b-HK$26,645,675,939.7566.8x-20.5x22.7x
Mon, 07 Dec 2020HK$351.8bHK$20.1b-HK$13,901,301,810.9743.2x-25.3x17.5x
Thu, 10 Sep 2020HK$337.6bHK$17.2b-HK$11,180,934,453.5952x-30.2x19.7x
Wed, 03 Jun 2020HK$249.8bHK$16.9b-HK$10,409,928,242.8730.4x-24x14.7x
Sat, 07 Mar 2020HK$184.8bHK$17.1b-HK$7,752,252,997.1835.8x-23.8x10.8x
Tue, 10 Dec 2019HK$162.5bHK$16.0b-HK$8,698,175,628.4325.4x-18.7x10.2x
Mon, 02 Sep 2019HK$118.2bHK$15.5b-HK$8,892,457,780.7213.5x-13.3x7.6x
Price to Earnings Ratio

-13.3x


Total Market Cap: HK$118.2bTotal Earnings: -HK$8,892,457,780.72Total Revenue: HK$15.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Hong Kong Biotech Industry Price to Earnings3Y Average -18.8x202020212022
Current Industry PE
  • Investors are pessimistic on the Hong Kong Biotechnology industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 14.7x is higher than the industry's current PS ratio of 10.2x.
Past Earnings Growth
  • The earnings for companies in the Biotechnology industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 28% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Comparison

How does Hong Kong Biotech compare with similar industries?

HK Market0.31%
Healthcare-1.82%
Biotech0.10%
Biotech0.10%
Industry PEThere is insufficient data on the sub-industries of this industry.
Forecasted GrowthThere is insufficient data on the sub-industries of this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
2171 CARsgen Therapeutics HoldingsHK$18.3616.2%
+HK$1.5b
-47.3%PS349x
9969 InnoCare PharmaHK$12.184.1%
+HK$846.9m
-47.2%PS17.7x
9926 AkesoHK$23.653.5%
+HK$672.8m
-45.8%PS75.8x
1877 Shanghai Junshi BiosciencesHK$32.301.9%
+HK$547.6m
-34.3%PS8.3x
9939 Kintor PharmaceuticalHK$14.869.1%
+HK$480.6m
-78.3%PS144.7x
Simply Wall St™
Simply Wall Street Pty Ltd
17-21 Bellevue Street, Surry Hills, Sydney
Download on the App StoreGet it on Google Play
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

9926

HK$23.65

Akeso

7D

3.5%

1Y

-45.8%

1530

HK$5.28

3SBio

7D

1.1%

1Y

-31.5%

2181

HK$0.51

Mabpharm

7D

-13.6%

1Y

-56.0%

9995

HK$51.70

RemeGen

7D

-4.6%

1Y

-50.5%